New York, USA – May 13, 2021 – IntegrateRNA, division established by Creative Biogene, spend years of efforts in offering complete solutions for RNA discovery, expression analysis, functional research and mechanism analysis. With innovative tools and solutions, IntegrateRNA enables researchers to explore the world of RNA on an unprecedented scale, and map all RNAs involved in cell life programs, human diseases, and drug discovery. Recently, Creative Biogene announced the release of its oligonucleotide conjugation services to facilitate diagnostic and drug delivery research.
IntegrateRNA uses chemical conjugation methods to connect functional ligands to oligonucleotides including siRNA, ASO, miRNA, to optimize the stability, cellular uptake and pharmacokinetic characteristics of therapeutic oligonucleotides. The clinical success achieved with naked oligonucleotides is not satisfactory, and the main obstacles are considered to be their instability to nucleases, lack of target specificity, and poor absorption and targeted delivery. In order to improve the unfavorable properties of therapeutic oligonucleotides, the covalent conjugation of various ligands is aimed at affecting biodistribution, cellular uptake, targeted delivery and pharmacokinetic properties. Conjugation ligands include peptides, proteins, carbohydrates, aptamers and small molecules.
Oligonucleotide conjugation services provided by IntegrateRNA include GalNAc-oligonucleotide conjugation, cholesterol-oligonucleotide conjugation, PEG-oligonucleotide conjugation, peptide-oligonucleotide conjugation, antibody-oligonucleoside acid binding, protein-oligonucleotide binding etc. Based on years of experience in oligonucleotide synthesis, modification and conjugation, IntegrateRNA provides single, double, triple or tetra GalNAc conjugated oligonucleotides. GalNAc conjugates are compatible with various ribose, base, and phosphate bond modifications.
The cholesterol/cholesterol-TEG conjugated oligonucleotide provided by IntegrateRNA contains a cholesterol group linked to the 5’end, 3’end or internal of the oligonucleotide. Based on many years of experience in oligonucleotide synthesis and modification, the RNA platform can couple cholesterol groups to modified siRNA, ASO and antagomirs to improve their stability and enhance cell uptake.
As a global supplier, IntegrateRNA provides high-quality functional PEG and PEG derivatives, which are essential for PEGylated therapeutic oligonucleotides. Based on the advanced PEGylation platform, IntegrateRNA uses chemical conjugation methods to produce customized PEGylated oligonucleotides. In addition, IntegrateRNA also provides complete PEGylation method development services, including PEG derivative screening, analysis and characterization, bioconjugation method development and optimization, and PEGylated oligonucleotide production.
IntegrateRNA has a wide range of chemical modification effects and can provide oligonucleotide and peptide synthesis for many years. With expertise in synthesis, modification and bioconjugation, IntegrateRNA can provide high-quality and high-yield customized peptide-oligonucleotide conjugates (POC). Based on a strict quality evaluation and quality control system, each POC will be strictly monitored during the synthesis process, purified by HPLC, and QC tested by mass spectrometry or gel electrophoresis.
“Based on expertise in synthesis, bioconjugation and purification, IntegrateRNA provides customized antibody-oligonucleotide conjugates (AOC) to customers worldwide. We have developed methods to attach oligonucleotides to target antibodies via terminal functional groups (eg protected sulfhydryl, maleimide).” said Marcia Brady, she also added, “IntegrateRNA relies on highly-skilled scientists to devote itself to biological conjugation and cross-linking technology to provide conjugation services. Our experienced technical team can assist customers in producing high-quality oligonucleotide conjugates, and can flexibly adapt to your special requirements.”
IntegrateRNA, as the division of Creative Biogene that holds a leading position in providing complete solutions for RNA research, has years of experience in next-generation sequencing and develops microarray platforms that enable researchers to explore the world of RNA on an unprecedented scale, and mapping all RNAs involved in cell life programs, human diseases, and drug discovery.